Approved by the Regents
May 15, 2008

PROMOTION RECOMMENDATION
UNIVERSITY OF MICHIGAN MEDICAL SCHOOL
DEPARTMENT OF PATHOLOGY

Cory M. Hogaboam, Ph.D., Associate Professor of Pathology, with tenure, Department of Pathology, Medical School, is recommended for promotion to Professor of Pathology, with tenure, Department of Pathology, Medical School.

Academic Degrees:

Ph.D.	1993	University of Calgary
B.Sc.	1989	University of Calgary

Professional Record:

2004-Present	Associate Professor of Pathology, University of Michigan
2002–2004	Assistant Professor of Pathology, University of Michigan
2001–2002	Assistant Research Scientist, Department of Pathology, University of Michigan
1998–2001	Research Investigator, Department of Pathology, University of Michigan

Summary of Evaluation:

Teaching: Dr. Hogaboam has always had a significant role in education, predominantly at the graduate student and postdoctoral level. He also provides important mentoring for undergraduate students. Since his promotion in 2004 to Associate Professor, he has supervised ten postdoctoral fellows, seven of whom are still in his laboratory, and two of whom are currently faculty members at other institutions. He has also been the supervisor of thirteen graduate and undergraduate students, many of whom have already received their Ph.D.'s. He also lectures in the graduate pathology course on inflammation and tissue repair and infectious basis of tissue fibrosis. In addition, he was the course organizer for global outreach supported courses on the pathobiology of inflammation and new therapeutic perspectives in chronic disease in Rio de Janeiro, Brazil, an indication of his exceptional commitment to education at the international level. Dr. Hogaboam is regarded as an effective and enthusiastic educator, whose students have had superb experiences working with him.

Research: Dr. Hogaboam is an internationally recognized expert in pulmonary fibrosis, allergy and asthma. He currently is the principal investigator on seven grants from industry including the Novartis Institute for Biomedical Research, Centocor Research and Development and Signal Pharmaceuticals. Almost all of these grants are for identification and validation of therapeutic targets for pulmonary fibrosis, asthma and drug-induced liver injury. He is also a co-investigator on an additional seven grants, mainly studying pulmonary fibrosis, but also liver regeneration and pulmonary allergy. Since his promotion to Associate Professor, he has been the author or co-

author of 41 publications in high-quality peer-reviewed journals, including the *American Journal of Pathology*, the *Journal of Immunology, Hepatology, FASED Journal,* and *Laboratory Investigation*, to name a few. In many of these publications, he is part of large groups analyzing pulmonary fibrosis and pulmonary allergy, areas in which he has made seminal contributions. He has been invited to present his work at multiple universities and medical centers, a Keystone Symposium, and at numerous scientific meetings. He also has four patents covering treatment of allergic airway disease and pulmonary fibrosis.

Recent and Significant Publications:

Pierce EM, Carpenter KJ, Jakubzick C, Kunkel SL, Flaherty KR, Martinez FJ, Hogaboam CM: Therapeutic targeting of CCL21 or CCR7 abrogates pulmonary fibrosis induced by the adoptive transfer of human pulmonary fibroblasts into immunodeficient mice. *Am J Pathol* 170:1152-1164, 2007.

Choi ES, Pierce EM, Jakubzick C, Carpenter KJ, Kunkel SL, Evanoff H, Martinez FJ, Flaherty KR, Moore BB, Toews GB, Colby TV, Kazerooni EA, Gross BH, Travis WD, Hogaboam CM: Focal interstitial CC chemokine receptor-7 (CCR7) expression in idiopathic interstitial pneumonia. *J Clin Pathol* 59: 28-39, 2006.

Carpenter KJ, Ewing JL, Schuh JM, Ness TL, Kunkel SL, Aparaci M, Miralpeix M, Hogaboam CM: Therapeutic targeting of CCR1 during chronic fungal asthma. *Br J Pharmacol* 145(8):1160-1172, 2005.

Jakubzick C, Choi ES, Carpenter KJ, Kunkel SL, Evanoff H, Martinez FJ, Puri RK, Flaherty KR, Toews GB, Colby TV, Kazerooni EA, Gross BH, Travis WD, Hogaboam CM: Human pulmonary fibroblasts exhibit altered IL-4 and IL-13 receptor subunit expression in Idiopathic Interstitial Pneumonia. *Am J Pathol* 164:1989-2001, 2004.

Choi ES, Jakubzick C, Kunkel SL, Evanoff H, Martinez FJ, Puri RK, Flaherty KR, Toews GB, Colby TV, Kazerooni EA, Gross BH, Travis WD, Hogaboam CM: Enhanced monocyte chemoattractant protein-3/CC chemokine Ligand-7 in usual interstitial pneumonia. *Am.J Resp Crit Care Med*, Sep 1; 170(5):508-515, 2004.

Service: Dr. Hogaboam has been a model of a service oriented academician. He is a Section Editor of the *Journal of Immunology* and a member of editorial boards of Current Immunology Review, BMC Immunology, the *Open Immunology Journal*, and *Pulmonary Diseases, Fibrogenesis and Tissue Repair*. He has also been an invited reviewer for numerous additional journals. He has been a grant reviewer for the Canadian Institute for Health Research, the National Institutes of Health, the Department of Veteran's Affairs and the British Wellcome Trust. At the University of Michigan, he has been a member of numerous committees, including the Committee on Student Biomedical Research, the Preliminary Examination Committee of the Department of Pathology, and the Graduate Student Affairs Committee of the Graduate Program in Immunology.

External Review:

Reviewer A: "Dr. Hogaboam's future is truly bright as he embarks on several novel and exciting areas related to chronic pulmonary disease....As he has in the past, he is actively pursuing new collaborations to move forward into novel areas that might ultimately yield novel therapeutics for these and other pulmonary diseases."

Reviewer B: "There really is no way to overstate the importance of Dr. Hogaboam's contribution to the literature with regards to providing key insight into various aspects of inflammatory diseases. Not only is he a recognized leader in pulmonary research, he has also made seminal contributions focusing on how chemokine signaling regulates liver disease and repair....Dr. Hogaboam has established a national/internationally recognized independent and well-funded research program. His publication record is envious and his work has made high impact within the field."

Reviewer C: "I could go on forever detailing Cory's many scientific accomplishments. But suffice to say that he exemplifies the epitome of an extremely successful independent scientist in all areas. He continues to excel in all the areas required for promotion to the rank of Associate Professor and has acquired an international reputation as an added measure."

Reviewer D: "Dr. Hogaboam has a solid base of NIH funding which is up for renewal and has been incredibly successful in garnering a broad base of research support from the biotech/pharmaceutical industry....individuals who are outstanding researchers, which Dr. Hogaboam clearly is, and who also translate their own basic research into innovative clinical trials are a very rare find."

Reviewer E: "The scholarship impact of Cory's work has been tremendous. He is a leader in the field of pulmonary immunobiology and has made seminal contributions to understanding the chemokine and chemokine receptor regulation of lung-specific fibrosis as well as infectious disease....it is clear that Cory has carved a scientific niche for himself in which he is a leader and continuously makes important contributions. Therefore, in my estimation he ranks in the top 5% of his peers in terms of scientific impact and scholarly achievement."

Reviewer F: "...he has distinguished himself as an outstanding collaborator in the field, both with the large chemokine/pathology community at UMich and with investigators at other institutions....His work is well-respected as evidenced by consistent publication in top specialty journals...In addition, he is frequently invited to speak at national and international meetings, is extremely well-funded through both R01 and pharmaceutical company grants, and has succeeded in placing his trainees in academic positions."

Summary of Recommendation:

Cory M. Hogaboam, Ph.D., has developed an international reputation in the field of chemokine biology involving lung disease, especially pulmonary fibrosis and pulmonary allergy and asthma. He has a solid record of scientific accomplishment and is an exemplary educator with a great record of service to his profession. I enthusiastically recommend Dr. Hogaboam for promotion to Professor, with tenure, in the Department of Pathology.

James O. Woolliscroft, M.D.
Dean
Lyle C. Roll Professor of Medicine

May 2008